contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


fleries-portfolio-company-kahr-bio-presents-positive-results-from-its-phase-ii-trial-with-dsp107-in-combination-with-anti-pd-l1-in-colorectal-cancer

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Flerie är en aktiv långsiktig life science-investerare med fokus på bioteknik- och läkemedelsinvesteringar globalt. Bolaget är baserat i Stockholm och London och förvaltar en portfölj med investeringar i Europa, Israel och USA. Huvudfokus ligger på att förse organisationer som främst verkar inom läkemedelsutveckling, med tjänster och resurser. Flerie grundades 2011 och har sitt huvudkontor i Stockholm.

Flerie

Stockholm, Sweden, June 3, 2025. Flerie AB’s (publ) portfolio company KAHR Bio has communicated that they have presented positive Phase II results at the 2025 ASCO Annual Meeting.The results...

<div class="mfn-preamble">Stockholm, Sweden, June 3, 2025. Flerie AB’s (publ) portfolio company KAHR Bio has communicated that they have presented positive Phase II results at the 2025 ASCO Annual Meeting.</div><div class="mfn-body">The results indicate that KAHR Bio’s drug DSP107, when combined with the anti-PD-L1 cancer immunotherapy atezolizumab, demonstrated anti-tumour activity, extended survival, and a favourable safety profile in patients with third-line microsatellite stable metastatic colorectal cancer, including those with liver metastases.KAHR Bio is an immunotherapy company developing novel bi-functional fusion proteins against difficult-to-treat cancers.“This marks a major step forward for KAHR Bio and its bi-functional fusion protein platform targeting large cancer indications with high unmet needs,” says Karl Elmqvist, Investment Manager at Flerie.Read KAHR Bio’s full press release here: <a rel="noopener" href="https://www.prnewswire.com/news-releases/kahr-bio-announces-positive-phase-2-results-of-dsp107-in-combination-with-anti-pd-l1-in-colorectal-cancer-302470389.html">https://www.prnewswire.com/news-releases/kahr-bio-announces-positive-phase-2-results-of-dsp107-in-combination-with-anti-pd-l1-in-colorectal-cancer-302470389.html</a>Flerie’s ownership in KAHR Bio amounts to 31%.For more information: Karl Elmqvist Email: <a rel="noopener" href="mailto:ir@flerie.com">ir@flerie.com</a>Flerie in brief Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit <a rel="noopener" href="http://www.flerie.com/">www.flerie.com</a></div><div class="mfn-footer mfn-attachment mfn-attachment-general">Attachments <a rel="noopener" href="https://storage.mfn.se/fbd6b098-2f9a-4897-8478-be6358b1d15c/fleries-portfolio-company-kahr-bio-presents-positive-results-from-its-phase-ii-trial-with-dsp107-in-combination-with-anti-pd-l1-in-colorectal-cancer.pdf" class="mfn-generated mfn-primary">Flerie’s portfolio company KAHR Bio presents positive results from its Phase II trial with DSP107 in combination with anti-PD-L1 in colorectal cancer</a></div>

Flerie’s portfolio company KAHR Bio presents positive results from its Phase II trial with DSP107 in combination with anti-PD-L1 in colorectal cancer